Northera droxidopa: Phase II started

Researchers began an open-label, U.S. Phase II trial to evaluate up to 600 mg oral droxidopa given thrice daily for 14 weeks in about 20 patients. Chelsea has rights to droxidopa outside of Japan, Kor...